Small is big: Phar­ma’s R&D brain drain con­tin­ues as GSK’s Chris Car­pen­ter jumps to up­start Ru­bius

The steady mi­gra­tion of top R&D ex­ecs out of Big Phar­ma and in­to lit­tle biotech is con­tin­u­ing this morn­ing.

Af­ter spend­ing the last decade in Big Phar­ma R&D, Chris Car­pen­ter is mak­ing the leap to biotech, join­ing the ris­ing star Ru­bius as chief med­ical of­fi­cer.

Car­pen­ter — a for­mer as­so­ciate pro­fes­sor at Har­vard Med, where he ran a lab for years — spent the last six years at GSK, where he wrapped up his stint as a se­nior VP and head of can­cer epi­ge­net­ics. He jumped from Har­vard to Mer­ck to GSK, where he was cred­it­ed with lead­ing the de­vel­op­ment of Votri­ent. And at Mer­ck he worked on MK-4827, which went on to be­come Tesaro’s PARP drug Ze­ju­la.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.